Table 2.

Clinical Progression of BPH in the MTOPS Trial

Risk Reduction (95% CI)
				Combination
				Doxazosin and
	Placebo	Doxazosin	Finasteride	Finasteride
Endpoint	(n = 737)	(n = 756)	(n = 768)	(n = 786)
Clinical progression of BPH	−	39 (20–53)	34 (14–50)	66 (54–76)
≥ 4-point ↑ IPSS	−	45 (25–60)	30 (6–48)	64 (48–75)
AUR	−	35 (−31–67)	68 (21–87)	81 (44–93)
Invasive therapy due to BPH	−	3 (−48–37)	64 (34–80)	67 (40–82)

AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CI, confidence interval; IPSS, International Prostate Symptom Score; MTOPS, Medical Therapy of Prostatic Symptoms. Data from McConnell JD et al.¹⁴